BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/14/2026 9:17:14 AM | Browse: 6 | Download: 33
 |
Received |
|
2025-11-24 01:49 |
|
Peer-Review Started |
|
2025-11-24 01:49 |
|
First Decision by Editorial Office Director |
|
2026-01-07 09:21 |
|
Return for Revision |
|
2026-01-07 10:19 |
|
Revised |
|
2026-01-15 10:04 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-02-10 02:48 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-02-10 07:28 |
|
Articles in Press |
|
2026-02-10 07:28 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-04-24 09:27 |
|
Publish the Manuscript Online |
|
2026-05-14 09:17 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Advancing human epidermal growth factor receptor 2-positive gastric cancer therapy: Toward targeted immunotherapy and antibody-drug conjugates
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jia-Ju Xu, Chun-Xiao Ni, Ping Wang, Li-Dong Qin and Jia-Ju Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Scientific Research Fund of Tai’an Science and Technology Agency |
No. 2019NS180 |
|
| Corresponding Author |
Jia-Ju Xu, MD, Department of Medical Oncology, Tai’an City Central Hospital, No. 29 Longtan Road, Tai’an 271000, Shandong Province, China. jiajuxu1101@163.com |
| Key Words |
Human epidermal growth factor receptor 2-positive gastric cancer; Drug resistance mechanisms; Antibody-drug conjugates; Immunotherapy; Precision medicine; Liquid biopsy; Multi-omics analysis |
| Core Tip |
The therapeutic profile of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is shifting to a paradigm where it is no longer dependent on the traditional HER2 inhibition. This change has been achieved by two important developments: potent antibody-drug conjugates and combined modality therapies targeting HER2, immune checkpoints, and chemotherapy. Our review provides a critical analysis of these approaches, deconstructs the multifaceted molecular basis of resistance, and conceptualizes a next-generation precision oncology framework combining real-time monitoring with liquid biopsy and analytics driven by artificial intelligence to outsmart gastric cancer evolution. |
| Publish Date |
2026-05-14 09:17 |
| Citation |
Xu JJ, Ni CX, Wang P, Qin LD, Xu JJ. Advancing human epidermal growth factor receptor 2-positive gastric cancer therapy: Toward targeted immunotherapy and antibody-drug conjugates. World J Gastrointest Oncol 2026; 18(5): 116882 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i5/116882.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i5.116882 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
